相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance
Kristen Jensen-Pergakes et al.
MOLECULAR CANCER THERAPEUTICS (2022)
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
Warren Fiskus et al.
BLOOD CANCER JOURNAL (2022)
Covalent inhibitors of EZH2: Design, synthesis and evaluation
Qiangsheng Zhang et al.
BIOMEDICINE & PHARMACOTHERAPY (2022)
Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects
Juan Xia et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Discovery of the First-in-Class G9a/GLP Covalent Inhibitors
Kwang-Su Park et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1
Warren Fiskus et al.
LEUKEMIA (2022)
Advances in covalent drug discovery
Lydia Boike et al.
NATURE REVIEWS DRUG DISCOVERY (2022)
Licochalcone A is a natural selective inhibitor of arginine methyltransferase 6
Shuai Gong et al.
BIOCHEMICAL JOURNAL (2021)
Protein arginine methyltransferase 5: a potential cancer therapeutic target
Yuanyang Yuan et al.
CELLULAR ONCOLOGY (2021)
Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity
Dirk Brehmer et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Targeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors
Yi Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Role of NSD1 as potential therapeutic target in tumor
Chao Yang et al.
PHARMACOLOGICAL RESEARCH (2021)
Protein arginine methyltransferases: promising targets for cancer therapy
Jee Won Hwang et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2021)
The Discovery of Two Novel Classes of 5,5-Bicyclic Nucleoside-Derived PRMT5 Inhibitors for the Treatment of Cancer
Ryan Quiroz et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Protein arginine methylation: from enigmatic functions to therapeutic targeting
Qin Wu et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
The Structure and Functions of PRMT5 in Human Diseases
Aishat Motolani et al.
LIFE-BASEL (2021)
Targeting the Nuclear Receptor-Binding SET Domain Family of Histone Lysine Methyltransferases for Cancer Therapy: Recent Progress and Perspectives
Aarajana Shrestha et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression
Meng Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Molecular basis for substrate recruitment to the PRMT5 methylosome
Kathleen M. Mulvaney et al.
MOLECULAR CELL (2021)
The N6-methyladenosine demethylase ALKBH5 negatively regulates the osteogenic differentiation of mesenchymal stem cells through PRMT6
Zhaofeng Li et al.
CELL DEATH & DISEASE (2021)
The discovery of SKLB-0335 as a paralog-selective EZH2 covalent inhibitor
Qiangsheng Zhang et al.
CHEMICAL COMMUNICATIONS (2021)
Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia
Szymon Klossowski et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Characterization of the Menin-MLL Interaction as Therapeutic Cancer Target
Krzysztof Brzezinka et al.
CANCERS (2020)
Symmetric Arginine Dimethylation Is Selectively Required for mRNA Splicing and the Initiation of Type I and Type III Interferon Signaling
Patrick J. Metz et al.
CELL REPORTS (2020)
Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong In Vivo Antitumor Activity
Shilin Xu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of a First-in-Class Protein Arginine Methyltransferase 6 (PRMT6) Covalent Inhibitor
Yudao Shen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis
Shinichiro Kato et al.
CANCER DISCOVERY (2020)
Downregulation of histone methyltransferase SET8 inhibits progression of hepatocellular carcinoma
Jianhua Wu et al.
SCIENTIFIC REPORTS (2020)
EZH2: a novel target for cancer treatment
Ran Duan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
EZH2-Targeted Therapies in Cancer: Hype or a Reality
Marie-Lisa Eich et al.
CANCER RESEARCH (2020)
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Franck Morschhauser et al.
LANCET ONCOLOGY (2020)
Covalent inhibition of NSD1 histone methyltransferase
Huang Huang et al.
NATURE CHEMICAL BIOLOGY (2020)
Preliminary Data on a Phase 1/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Eunice S. Wang et al.
BLOOD (2020)
Developing protein arginine methyltransferase 1 (PRMT1) inhibitor TC-E-5003 as an antitumor drug using INEI drug delivery systems
Pengcheng Zhang et al.
DRUG DELIVERY (2020)
Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors
Hong Lin et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
The dynamic conformational landscape of the protein methyltransferase SETD8
Shi Chen et al.
ELIFE (2019)
Role of protein arginine methyltransferase 5 in human cancers
Wendi Xiao et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction
Angelo Aguilar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression
Cristina Segovia et al.
NATURE MEDICINE (2019)
The regulation, functions and clinical relevance of arginine methylation
Ernesto Guccione et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
Targeting epigenetic machinery: Emerging novel allosteric inhibitors
Fei Ye et al.
PHARMACOLOGY & THERAPEUTICS (2019)
The role and prospect of JMJD3 in stem cells and cancer
Xiaojiao Yin et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas
Makoto Yamagishi et al.
CELL REPORTS (2019)
Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia
Yufei Chen et al.
EXPERIMENTAL HEMATOLOGY (2019)
A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia
Andrei V. Krivtsov et al.
CANCER CELL (2019)
LKB1 regulates PRMT5 activity in breast cancer
Hanine Lattouf et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)
Pei-Pei Kung et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Pharmacologic Inhibition of the Menin-MLL Interaction Leads to Transcriptional Repression of PEG10 and Blocks Hepatocellular Carcinoma
Katarzyna Kempinska et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction
Shilin Xu et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2018)
Targeting Epigenetics in Cancer
Richard L. Bennett et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 58 (2018)
Significant association of PRMT6 hypomethylation with colorectal cancer
Ranran Pan et al.
JOURNAL OF CLINICAL LABORATORY ANALYSIS (2018)
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Antoine Italiano et al.
LANCET ONCOLOGY (2018)
Enhancer of zeste homolog 2 (EZH2) inhibitors
Nitya Gulati et al.
LEUKEMIA & LYMPHOMA (2018)
LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity
Zahid Q. Bonday et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
BCL11A interacts with SOX2 to control the expression of epigenetic regulators in lung squamous carcinoma
Kyren A. Lazarus et al.
NATURE COMMUNICATIONS (2018)
Emerging EZH2 Inhibitors and Their Application in Lymphoma
Jennifer K. Lue et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2018)
MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis
William B. Tu et al.
CANCER CELL (2018)
Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer
Harshita Shailesh et al.
Oncotarget (2018)
Tackling malignant melanoma epigenetically: histone lysine methylation
Elias Orouji et al.
CLINICAL EPIGENETICS (2018)
Inhibitors of Protein Methyltransferases and Demethylases
H. Umit Kaniskan et al.
CHEMICAL REVIEWS (2018)
Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin
Laurie K. Svoboda et al.
ONCOTARGET (2017)
The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy
Dai Shimizu et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
Discovery of Potent and Selective Inhibitors for G9a-Like Protein (GLP) Lysine Methyltransferase
Yan Xiong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes
Ashwin Unnikrishnan et al.
CELL REPORTS (2017)
The Role of Nuclear Receptor-Binding SET Domain Family Histone Lysine Methyltransferases in Cancer
Richard L. Bennett et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma
Kevin Brennan et al.
SCIENTIFIC REPORTS (2017)
G9a-An Appealing Antineoplastic Target
Wei-Lin Chen et al.
CURRENT CANCER DRUG TARGETS (2017)
Structure-activity relationship studies of G9a-like protein (GLP) inhibitors
Yan Xiong et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2017)
A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination
Xu Wang et al.
EMBO JOURNAL (2017)
A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases
Mohammad S. Eram et al.
ACS CHEMICAL BIOLOGY (2016)
Protein Arginine Methyltransferase 6 (Prmt6) Is Essential for Early Zebrafish Development through the Direct Suppression of gadd45a Stress Sensor Gene
Xin-Xi Zhao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Severe Hypomyelination and Developmental Defects Are Caused in Mice Lacking Protein Arginine Methyltransferase 1 (PRMT1) in the Central Nervous System
Misuzu Hashimoto et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
SET8 induces epithelial-mesenchymal transition and enhances prostate cancer cell metastasis by cooperating with ZEB1
Liejun Hou et al.
MOLECULAR MEDICINE REPORTS (2016)
Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666
Kenneth W. Duncan et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Targeted Covalent Inhibitors for Drug Design
Thomas A. Baillie
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Structural basis of arginine asymmetrical dimethylation by PRMT6
Hong Wu et al.
BIOCHEMICAL JOURNAL (2016)
Structure-based screening and optimization of cytisine derivatives as inhibitors of the menin-MLL interaction
Hai-Jing Zhong et al.
CHEMICAL COMMUNICATIONS (2016)
Progress in the Development of Lysine Methyltransferase SETD8 Inhibitors
Ciro Milite et al.
CHEMMEDCHEM (2016)
Small Molecule Inhibitors of Protein Arginine Methyltransferases
Hao Hu et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development
David S. Rogawski et al.
FUTURE MEDICINAL CHEMISTRY (2016)
A PWWP Domain of Histone-Lysine N-Methyltransferase NSD2 Binds to Dimethylated Lys-36 of Histone H3 and Regulates NSD2 Function at Chromatin
Saumya M. Sankaran et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas
Rishi G. Vaswani et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6
Yudao Shen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Structure-Based Design of a Covalent Inhibitor of the SET Domain-Containing Protein 8 (SETD8) Lysine Methyltransferase
Kyle V. Butler et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
The Role of Protein Arginine Methyltransferases in Inflammatory Responses
Ji Hye Kim et al.
MEDIATORS OF INFLAMMATION (2016)
Mechanism of G9a inhibitor BIX-01294 acting on U251 glioma cells
Ai-Shun Guo et al.
MOLECULAR MEDICINE REPORTS (2016)
Identification of novel small-molecule inhibitors targeting menin-MLL interaction, repurposing the antidiarrheal loperamide
Liyan Yue et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2016)
Epigenetic modulators as therapeutic targets in prostate cancer
Ines Graca et al.
CLINICAL EPIGENETICS (2016)
Chemical Biology of Protein Arginine Modifications in Epigenetic Regulation
Jakob Fuhrmann et al.
CHEMICAL REVIEWS (2015)
SET8 expression is associated with overall survival in gastric cancer
X. L. Shi et al.
GENETICS AND MOLECULAR RESEARCH (2015)
Protein Arginine Methyltransferase 6 Enhances Polyglutamine-Expanded Androgen Receptor Function and Toxicity in Spinal and Bulbar Muscular Atrophy
Chiara Scaramuzzino et al.
NEURON (2015)
Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound
Lorna H. Mitchell et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
The NSD family of protein methyltransferases in human cancer
Theodore Vougiouklakis et al.
EPIGENOMICS (2015)
Effect of phosphorylation and methylation on the function of the p16INK4a protein in non-small cell lung cancer A549 cells
Wen-Long Ma et al.
ONCOLOGY LETTERS (2015)
PRMT6 increases cytoplasmic localization of p21CDKN1A in cancer cells through arginine methylation and makes more resistant to cytotoxic agents
Makoto Nakakido et al.
ONCOTARGET (2015)
Small-Molecule Inhibitors of SETD8 with Cellular Activity
Gil Blum et al.
ACS CHEMICAL BIOLOGY (2014)
A Sensitive Luminescent Assay for the Histone Methyltransferase NSD1 and Other SAM-Dependent Enzymes
Katherine M. Drake et al.
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES (2014)
Histone H4 Lys 20 methyltransferase SET8 promotes androgen receptor-mediated transcription activation in prostate cancer
Lushuai Yao et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
Protein arginine methylation of non-histone proteins and its role in diseases
Han Wei et al.
CELL CYCLE (2014)
Deregulated expression of selected histone methylases and demethylases in prostate carcinoma
Filipa Quintela Vieira et al.
ENDOCRINE-RELATED CANCER (2014)
Challenges and opportunities in targeting the menin- MLL interaction
Tomasz Cierpicki et al.
FUTURE MEDICINAL CHEMISTRY (2014)
Tumor Necrosis Factor (TNF)-α Induction of CXCL10 in Endothelial Cells Requires Protein Arginine Methyltransferase 5 (PRMT5)-mediated Nuclear Factor (NF)-κB p65 Methylation
Daniel P. Harris et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Methyltransferase G9A regulates T cell differentiation during murine intestinal inflammation
Frann Antignano et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
High-Affinity Small-Molecule Inhibitors of the Menin-Mixed Lineage Leukemia (MLL) Interaction Closely Mimic a Natural Protein-Protein Interaction
Shihan He et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Discovery of a Selective, Substrate-Competitive Inhibitor of the Lysine Methyltransferase SETD8
Anqi Ma et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis
Kuo-Tai Hua et al.
MOLECULAR CANCER (2014)
Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells
Bin E. Li et al.
BLOOD (2013)
Contributions of the Histone Arginine Methyltransferase PRMT6 to the Epigenetic Function of RUNX1
Joern Lausen
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION (2013)
Asymmetric Dimethylarginine (ADMA): A Promising Biomarker for Cardiovascular Disease?
Georgios Bouras et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2013)
Deregulation of protein methylation in melanoma
Katharina Limm et al.
EUROPEAN JOURNAL OF CANCER (2013)
Overexpression of PRMT5 Promotes Tumor Cell Growth and Is Associated with Poor Disease Prognosis in Epithelial Ovarian Cancer
Xiangxiang Bao et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2013)
Dynamic Methylation of Numb by Set8 Regulates Its Binding to p53 and Apoptosis
Gurpreet Kaur Dhami et al.
MOLECULAR CELL (2013)
Arginine Methylation-Dependent Reader-Writer Interplay Governs Growth Control by E2F-1
Shunsheng Zheng et al.
MOLECULAR CELL (2013)
EHMT1 controls brown adipose cell fate and thermogenesis through the PRDM16 complex
Haruya Ohno et al.
NATURE (2013)
Histone arginine methylation keeps RUNX1 target genes in an intermediate state
J. Herglotz et al.
ONCOGENE (2013)
Protein arginine methyltransferases and cancer
Yanzhong Yang et al.
NATURE REVIEWS CANCER (2013)
Novel Inhibitors for PRMT1 Discovered by High-Throughput Screening Using Activity-Based Fluorescence Polarization
Myles B. C. Dillon et al.
ACS CHEMICAL BIOLOGY (2012)
Histone Lysine Methyltransferase SETD8 Promotes Carcinogenesis by Deregulating PCNA Expression
Masashi Takawa et al.
CANCER RESEARCH (2012)
Arginine methylation controls growth regulation by E2F-1
Er-Chieh Cho et al.
EMBO JOURNAL (2012)
Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes
Dennis H. Dowhan et al.
ENDOCRINE-RELATED CANCER (2012)
PR-Set7 and H4K20me1: at the crossroads of genome integrity, cell cycle, chromosome condensation, and transcription
David B. Beck et al.
GENES & DEVELOPMENT (2012)
Suppression of PRMT6-mediated arginine methylation of p16 protein potentiates its ability to arrest A549 cell proliferation
Xiuli Wang et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2012)
Protein Arginine Methyltransferases (PRMTs): Promising Targets for the Treatment of Pulmonary Disorders
Dariusz Zakrzewicz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)
Ablation of PRMT6 reveals a role as a negative transcriptional regulator of the p53 tumor suppressor
Mathieu Neault et al.
NUCLEIC ACIDS RESEARCH (2012)
The arginine methyltransferase PRMT6 regulates cell proliferation and senescence through transcriptional repression of tumor suppressor genes
Claudia Stein et al.
NUCLEIC ACIDS RESEARCH (2012)
Crystal structure of the human PRMT5:MEP50 complex
Stephen Antonysamy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Protein Arginine Methyltransferase 6 Regulates Embryonic Stem Cell Identity
Yun Hwa Lee et al.
STEM CELLS AND DEVELOPMENT (2012)
High-Resolution Genome-wide Mapping of the Primary Structure of Chromatin
Zhenhai Zhang et al.
CELL (2011)
Regulation of chromatin by histone modifications
Andrew J. Bannister et al.
CELL RESEARCH (2011)
Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers
Masanori Yoshimatsu et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells
Masoud Vedadi et al.
NATURE CHEMICAL BIOLOGY (2011)
A Chloroacetamidine-Based Inactivator of Protein Arginine Methyltransferase 1: Design, Synthesis, and In Vitro and In Vivo Evaluation
Obiamaka Obianyo et al.
CHEMBIOCHEM (2010)
Dynamic regulation of the PR-Set7 histone methyltransferase is required for normal cell cycle progression
Shumin Wu et al.
GENES & DEVELOPMENT (2010)
Molecular Basis of the Mixed Lineage Leukemia-Menin Interaction IMPLICATIONS FOR TARGETING MIXED LINEAGE LEUKEMIAS
Jolanta Grembecka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Involvement of Histone H3 Lysine 9 (H3K9) Methyltransferase G9a in the Maintenance of HIV-1 Latency and Its Reactivation by BIX01294
Kenichi Imai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
G9a and Glp Methylate Lysine 373 in the Tumor Suppressor p53
Jing Huang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis
Shenghao Jin et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization
S. Goyama et al.
LEUKEMIA (2010)
Protein arginine methyltransferase 6 regulates multiple aspects of gene expression
Matthew J. Harrison et al.
NUCLEIC ACIDS RESEARCH (2010)
Methylation of the Tumor Suppressor Protein, BRCA1, Influences Its Transcriptional Cofactor Function
Irene Guendel et al.
PLOS ONE (2010)
Essential Role of the Histone Methyltransferase G9a in Cocaine-Induced Plasticity
Ian Maze et al.
SCIENCE (2010)
Methylation, a key step for nongenomic estrogen signaling in breast tumors
M. Le Romancer et al.
STEROIDS (2010)
Further clinical and molecular delineation of the 9q subtelomeric deletion syndrome supports a major contribution of EHMT1 haploinsufficiency to the core phenotype
T. Kleefstra et al.
JOURNAL OF MEDICAL GENETICS (2009)
Arginine Methylation Regulates Telomere Length and Stability
Taylor R. H. Mitchell et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Distinct Roles for Histone Methyltransferases G9a and GLP in Cancer Germ-Line Antigen Gene Regulation in Human Cancer Cells and Murine Embryonic Stem Cells
Petra A. Link et al.
MOLECULAR CANCER RESEARCH (2009)
Protein Arginine Methylation in Mammals: Who, What, and Why
Mark T. Bedford et al.
MOLECULAR CELL (2009)
Impaired PRMT1 activity in the liver and pancreas of type 2 diabetic Goto-Kakizaki rats
Hiroaki Iwasaki
LIFE SCIENCES (2009)
Control of Cognition and Adaptive Behavior by the GLP/G9a Epigenetic Suppressor Complex
Anne Schaefer et al.
NEURON (2009)
The physiological and pathophysiological role of PRMT1-mediated protein arginine methylation
Thomas B. Nicholson et al.
PHARMACOLOGICAL RESEARCH (2009)
Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells
Hideo Watanabe et al.
Cancer Cell International (2008)
A chromatin-wide transition to H4K20 monomethylation impairs genome integrity and programmed DNA rearrangements in the mouse
Gunnar Schotta et al.
GENES & DEVELOPMENT (2008)
A glycine-arginine domain in control of the human MRE11 DNA repair protein
Ugo Dery et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Ezh1 and Ezh2 Maintain Repressive Chromatin through Different Mechanisms
Raphael Margueron et al.
MOLECULAR CELL (2008)
EZH1 Mediates Methylation on Histone H3 Lysine 27 and Complements EZH2 in Maintaining Stem Cell Identity and Executing Pluripotency
Xiaohua Shen et al.
MOLECULAR CELL (2008)
Arginine methylation regulates the p53 response
Martin Jansson et al.
NATURE CELL BIOLOGY (2008)
Protein lysine methyltransferase G9a acts on non-histone targets
Philipp Rathert et al.
NATURE CHEMICAL BIOLOGY (2008)
Downregulation of Histone H3 Lysine 9 Methyltransferase G9a Induces Centrosome Disruption and Chromosome Instability in Cancer Cells
Yutaka Kondo et al.
PLOS ONE (2008)
Plasma concentration of asymmetric climethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy
Maria Lajer et al.
DIABETES CARE (2008)
Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia
Yali Dou et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2008)
PR-Set7-dependent lysine methylation ensures genome replication and stability through S phase
Mathieu Tardat et al.
JOURNAL OF CELL BIOLOGY (2007)
Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive
Ernesto Guccione et al.
NATURE (2007)
Protein arginine-methyltransferase-dependent oncogenesis
Ngai Cheung et al.
NATURE CELL BIOLOGY (2007)
Modulation of p53 function by SET8-mediated methylation at lysine 382
Xiaobing Shi et al.
MOLECULAR CELL (2007)
Interaction of MLL amino terminal sequences with menin is required for transformation
Corrado Caslini et al.
CANCER RESEARCH (2007)
High-resolution profiling of histone methylations in the human genome
Artern Barski et al.
CELL (2007)
Chromatin modifications and their function
Tony Kouzarides
CELL (2007)
Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase
Stefan Kubicek et al.
MOLECULAR CELL (2007)
Methylation of lysine 4 on histone H3: Intricacy of writing and reading a single epigenetic mark
Alexander J. Ruthenburg et al.
MOLECULAR CELL (2007)
Role of the polycomb repressive complex 2 in acute promyelocytic leukemia
Raffaella Villa et al.
CANCER CELL (2007)
Arginine methylation regulates DNA polymerase β
N El-Andaloussi et al.
MOLECULAR CELL (2006)
The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression
YX Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The GAR motif of 53BP1 is arginine methylated by PRMT1 and is necessary for 53BP1 DNA binding activity
FM Boisvert et al.
CELL CYCLE (2005)
The diverse functions of histone lysine methylation
C Martin et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2005)
The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis
A Yokoyama et al.
CELL (2005)
The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype
PA Croonquist et al.
ONCOGENE (2005)
Structural and functional analysis of SET8, a histone H4 Lys-20 methyltransferase
JF Couture et al.
GENES & DEVELOPMENT (2005)
MLL: How complex does it get?
R Popovic et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2005)
Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9
M Tachibana et al.
GENES & DEVELOPMENT (2005)
Arginine methylation of MRE11 by PRMT1 is required for DNA damage checkpoint control
FM Boisvert et al.
GENES & DEVELOPMENT (2005)
Increased expression of EZH2, a polycomb group protein, in bladder carcinoma
S Arisan et al.
UROLOGIA INTERNATIONALIS (2005)
Menin associates with a trithorax family histone methyltransferase complex and with the Hoxc8 locus
CM Hughes et al.
MOLECULAR CELL (2004)
Regulation of p53 activity through lysine methylation
S Chuikov et al.
NATURE (2004)
Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization
BB Zeisig et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells
CG Kleer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9
PM Ayton et al.
GENES & DEVELOPMENT (2003)
The polycomb group protein EZH2 is involved in progression of prostate cancer
S Varambally et al.
NATURE (2002)
G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis
M Tachibana et al.
GENES & DEVELOPMENT (2002)
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
SA Armstrong et al.
NATURE GENETICS (2002)
Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma
FJ van Kemenade et al.
BLOOD (2001)
PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells
J Tang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
